Charles River Laboratories International Inc.

NYSE:CRL   3:59:37 PM EDT
360.92
+7.22 (+2.04%)
Other Pre-Announcement, Mergers / Acquisitions

Charles River Laboratories To Acquire Vigene Biosciences For Purchase Price Of $292.5 Mln In Cash

Published: 05/17/2021 11:16 GMT
Charles River Laboratories International Inc. (CRL) - Charles River Laboratories to Acquire Vigene Biosciences to Enhance Gene Therapy Capabilities.
Charles River Laboratories International Inc - Purchase Price is Expected to Be $292.5 Million in Cash.
Charles River Laboratories International Inc - Transaction Includes Contingent Additional Payments of Up to $57.5 Million Based on Future Performance.
Charles River Laboratories International Inc - Deal Expected to Be Accretive to Charles River's Long-term Revenue and Earnings per Share Growth.
Charles River Laboratories International - Vigene is Expected to Add About 50 Basis Points to Charles River's Reported Revenue Growth Rate in 2021.
Charles River Laboratories International - Deal and Associated Fees Expected to Be Financed Through Charles River's Existing Credit Facility and Cash.
Charles River Laboratories International Inc - Vigene is Expected to Be Reported As Part of Charles River's Manufacturing Segment.